Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion
SARS-CoV-2 monoclonal antibodies (mAbs) have been proposed as a treatment for mild to moderate COVID-19, with favorable outcomes reported in clinical trials and an emergency use authorization granted by the Food and Drug Administration. Real-world data remain limited, however, and thus this analysis...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Elsevier
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/05b2db2ae16a4bb2be783a8b09ce7830 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|